Retrieve available abstracts of 460 articles: HTML format
Single Articles
June 2025
MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically
Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from
an Entire Country.
J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996. PubMedAbstract available
BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy
of Prostate Cancer.
J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751. PubMedAbstract available
YUE J, Zhang Y, Miu Y, Zhao Y, et al Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity.
J Nucl Med. 2025 Jun 12:jnumed.125.269868. doi: 10.2967/jnumed.125.269868. PubMed
KWON D, Li EJ, Dulal C, Daube-Witherspoon M, et al Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study
with [(18)F]FGln and [(18)F]FDG.
J Nucl Med. 2025 Jun 12:jnumed.124.268831. doi: 10.2967/jnumed.124.268831. PubMedAbstract available
DRZEZGA A, Barthel H Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than
Competition.
J Nucl Med. 2025;66. PubMedAbstract available
FANTI S, Robles Barba JJ, Behr S, Maurer T, et al Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically
Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective
Multicenter Study.
J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266. PubMedAbstract available
IAGARU A, Suarez JF, Behr S, Aggarwal R, et al Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors
Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3
Prospective Multicenter Study.
J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007. PubMedAbstract available
GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071. PubMedAbstract available
MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for
Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931. PubMedAbstract available
COOLS R, Vermeulen K, Vonck E, Baekelandt V, et al In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with
[(11)C]HSP990 in Healthy Aging and Neurodegeneration.
J Nucl Med. 2025;66:940-947. PubMedAbstract available
KAYAL G, Roseland ME, Wang C, Fitzpatrick K, et al Multicycle Dosimetric Behavior and Dose-Effect Relationships in
[(177)Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
J Nucl Med. 2025;66:900-908. PubMedAbstract available
May 2025
PALARD-NOVELLO X, Visser D, Yaqub M, van de Giessen E, et al Whole-Body [(18)F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial
Field of View.
J Nucl Med. 2025 May 29:jnumed.124.268979. doi: 10.2967/jnumed.124.268979. PubMedAbstract available
LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced
Obesity Model of Breast Cancer.
J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938. PubMedAbstract available
LILBURN DML, Garthwaite HS, Ganeshan B, Win T, et al [(18)F]FDG PET/CT Predicts Patient Survival in Patients with Systemic
Sclerosis-Associated Interstitial Lung Disease.
J Nucl Med. 2025 May 29:jnumed.125.269497. doi: 10.2967/jnumed.125.269497. PubMedAbstract available
AKHAVANALLAF A, Lu Z, Peterson AB, Blakkisrud J, et al Can (177)Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET?
Findings from Multicenter Data.
J Nucl Med. 2025 May 22:jnumed.124.269098. doi: 10.2967/jnumed.124.269098. PubMedAbstract available
TRAUTWEIN NF, Mattern S, Hinterleitner M, Reischl G, et al Histologic Ex Vivo Validation of the [(18)F]SITATE Somatostatin Receptor PET
Tracer.
J Nucl Med. 2025 May 22:jnumed.125.269619. doi: 10.2967/jnumed.125.269619. PubMedAbstract available
RAMOS CD Redefining Nuclear Medicine: "Biodistribution" Should Be the Core Concept.
J Nucl Med. 2025 May 22:jnumed.125.270245. doi: 10.2967/jnumed.125.270245. PubMed
MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al Reply to "(176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue
for Patient Safety".
J Nucl Med. 2025 May 15:jnumed.125.270027. doi: 10.2967/jnumed.125.270027. PubMed
ZHANG W, Yao W, Shen G [(68)Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear
Factor-kappaB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with
Histopathology.
J Nucl Med. 2025 May 15:jnumed.124.269432. doi: 10.2967/jnumed.124.269432. PubMed
CARTER LM, Milman R, Ocampo Ramos JC, Kesner AL, et al (176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for
Patient Safety.
J Nucl Med. 2025 May 15:jnumed.125.269846. doi: 10.2967/jnumed.125.269846. PubMed
BAILEY DL, Meikle SR, Calamante F, Angelis G, et al The Australian National Total-Body PET Facility-A Shared Resource and Risk Model
for Implementing Total-Body PET.
J Nucl Med. 2025 May 15:jnumed.125.269859. doi: 10.2967/jnumed.125.269859. PubMed
ZHAO Q, Liow JS, Jee JE, Montero Santamaria J, et al [(11)C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey
Brain Phosphodiesterase Type 4 Subtype B.
J Nucl Med. 2025 May 8:jnumed.124.269159. doi: 10.2967/jnumed.124.269159. PubMedAbstract available
YEH R, Pareja F, Shobeiri P, Ross D, et al Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with
Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227. PubMedAbstract available
DUBROFF JG, Hsieh CJ, Wiers CE, Lee H, et al [(11)C]Carfentanil PET Whole-Body Imaging of mu-Opioid Receptors: A First in-Human
Study.
J Nucl Med. 2025 May 8:jnumed.124.269413. doi: 10.2967/jnumed.124.269413. PubMedAbstract available
ICHIJO S, Arisawa T, Hatano M, Nakajima W, et al First-in-Human Study of (18)F-Labeled PET Tracer for Glutamate AMPA Receptor
[(18)F]K-40: A Derivative of [(11)C]K-2.
J Nucl Med. 2025 May 8:jnumed.124.269405. doi: 10.2967/jnumed.124.269405. PubMedAbstract available
ZARAGORI T, Chevalier E, Citerne Q, Roch V, et al Assessment of [(177)Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body
Recordings Provided by a 360 degrees Cadmium-Zinc-Telluride Camera Compared with Results
from a Conventional Anger-Camera Protocol.
J Nucl Med. 2025;66:771-777. PubMedAbstract available
PICHLER V, Schwingenschlogl-Maisetschlager V, Duman I, Monforte X, et al Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic
Precision for Unprecedented Preclinical Insights in Molecular Imaging.
J Nucl Med. 2025;66:813-816. PubMedAbstract available
TOURNIER N, Langer O Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in
Neurologic Diseases: Radiotracer Selection Criteria.
J Nucl Med. 2025;66:676-680. PubMedAbstract available
April 2025
CHUNG KJ, Chaudhari AJ, Nardo L, Jones T, et al Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early
Dynamic (18)F-FDG PET Kinetic Modeling.
J Nucl Med. 2025 Apr 30:jnumed.124.268706. doi: 10.2967/jnumed.124.268706. PubMedAbstract available
FROEHNER M, Zophel K (177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
J Nucl Med. 2025 Apr 30:jnumed.125.269875. doi: 10.2967/jnumed.125.269875. PubMed
FELBER V, Holzleitner N, Joksch M, Suhrbier T, et al First-in-Human Serum Stability Studies of [(177)Lu]Lu-AMTG: A Step Toward
Improved GRPR-Targeted Radiopharmaceutical Therapy.
J Nucl Med. 2025 Apr 30:jnumed.124.269132. doi: 10.2967/jnumed.124.269132. PubMedAbstract available
WENZEL M, Groener D, Chun FKH, Mandel P, et al Reply to "(177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?".
J Nucl Med. 2025 Apr 30:jnumed.125.270028. doi: 10.2967/jnumed.125.270028. PubMed
TRIVIERI MG, Devesa A, Robson PM, Bose S, et al Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI
and DECT Imaging in Long COVID Patients.
J Nucl Med. 2025 Apr 30:jnumed.124.268980. doi: 10.2967/jnumed.124.268980. PubMedAbstract available
PARIHAR AS, Pant N, Heidari P, Fong L, et al Approaches to Imaging Immune Activation Using PET.
J Nucl Med. 2025 Apr 30:jnumed.124.268289. doi: 10.2967/jnumed.124.268289. PubMedAbstract available
SHI B, Zhang Y, Wu S, Xu D, et al CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal
Carcinoma: A Proof-of-Concept Study.
J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585. PubMedAbstract available
FRANCA VELO A, Giantini Larsen A, Humm JL, Zanzonico P, et al Determination of the Intralesional Distribution of Theranostic (124)I-Omburtamab
Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.
J Nucl Med. 2025 Apr 30:jnumed.124.267995. doi: 10.2967/jnumed.124.267995. PubMedAbstract available
DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for
Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387. PubMedAbstract available
ZIMMERMANN R, Beyer T Stakeholders of Theranostics: Thomas Beyer Talks with Richard Zimmermann About
the Golden Age of Nuclear Medicine.
J Nucl Med. 2025 Apr 24:jnumed.125.270085. doi: 10.2967/jnumed.125.270085. PubMed
UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA
Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Using Real-World Data.
J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431. PubMedAbstract available
SMITH CLC, Zwezerijnen GJC, den Hollander ME, Zijlstra JM, et al Feasibility of Ultra-Low-Activity (18)F-FDG PET/CT Imaging Using a
Long-Axial-Field-of-View PET/CT System.
J Nucl Med. 2025 Apr 24:jnumed.124.269272. doi: 10.2967/jnumed.124.269272. PubMedAbstract available
THACKERAY JT 2024 SNMMI Highlights Lecture: Cardiovascular Sciences.
J Nucl Med. 2025 Apr 24:jnumed.125.269988. doi: 10.2967/jnumed.125.269988. PubMedAbstract available
DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of
Investigational PET Radiopharmaceuticals.
J Nucl Med. 2025 Apr 17:jnumed.125.269885. doi: 10.2967/jnumed.125.269885. PubMed
SCHINDLER TH, Bateman TM, Berman DS, Chareonthaitawee P, et al FDA Approval of (18)F-Flurpiridaz Is for PET: Stepping into a New Area of
Myocardial Perfusion Imaging?
J Nucl Med. 2025 Apr 17:jnumed.124.269154. doi: 10.2967/jnumed.124.269154. PubMed
ALBERTS I, More S, Knapp K, Mei R, et al Is Long-Axial-Field-of-View PET/CT Cost-Effective? An International
Health-Economic Analysis.
J Nucl Med. 2025 Apr 17:jnumed.124.269203. doi: 10.2967/jnumed.124.269203. PubMedAbstract available
BRUMBERG J, Schroter N, Blazhenets G, Omrane MA, et al [(18)F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients
with Suspected 4-Repeat Tauopathies.
J Nucl Med. 2025 Apr 17:jnumed.124.268956. doi: 10.2967/jnumed.124.268956. PubMedAbstract available
FAROLFI A, Casadei B, Malizia C, Ussia R, et al Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After
1 and 3 Months: A Prospective Single-Center Study.
J Nucl Med. 2025 Apr 17:jnumed.125.269670. doi: 10.2967/jnumed.125.269670. PubMedAbstract available
HACHEY JS, Viray TD, Matasci M, Ravazza D, et al Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of
Triple-Negative Breast Cancer.
J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859. PubMedAbstract available
DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA
PET/CT.
J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361. PubMedAbstract available
SARI H, Teimoorisichani M, Viscione M, Mingels C, et al Feasibility of an Ultra-Low-Dose PET Scan Protocol with CT-Based and LSO-TX-Based
Attenuation Correction Using a Long-Axial-Field-of-View PET/CT Scanner.
J Nucl Med. 2025 Apr 10:jnumed.124.268380. doi: 10.2967/jnumed.124.268380. PubMedAbstract available
ZHANG Y, Yue J, Yang X, Fei G, et al [(68)Ga]Ga-RAYZ-8009: A Peptide PET Tracer for Targeting HCC in Humans.
J Nucl Med. 2025 Apr 10:jnumed.124.269294. doi: 10.2967/jnumed.124.269294. PubMed
HICKS RJ Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
J Nucl Med. 2025 Apr 3:jnumed.125.269496. doi: 10.2967/jnumed.125.269496. PubMed
BARRY N, Kendrick J, Rowshanfarzad P, Hassan GM, et al An External, Independent Validation of an O-(2-[(18)F]Fluoroethyl)-l-Tyrosine PET
Automatic Segmentation Network on a Single-Center, Prospective Dataset of
Patients with Glioblastoma.
J Nucl Med. 2025 Apr 3:jnumed.124.268925. doi: 10.2967/jnumed.124.268925. PubMedAbstract available
LEE Y, Nguyen TD, Du Y, Coughlin JM, et al Validating the Utility of Supervised Clustering Algorithm for Precise
[(11)C]DPA-713 PET Brain Image Quantification.
J Nucl Med. 2025 Apr 3:jnumed.124.268519. doi: 10.2967/jnumed.124.268519. PubMedAbstract available
SCHOLTISSEK H, Reitsam NG, Dierks A, Kroncke T, et al Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3-Directed
PET/CT.
J Nucl Med. 2025 Apr 3:jnumed.124.269290. doi: 10.2967/jnumed.124.269290. PubMed
GIORGIO J, Soleimani-Meigooni DN, Janabi M, Baker SL, et al Imaging Synaptic Density in Aging and Alzheimer Disease with [(18)F]SynVesT-1.
J Nucl Med. 2025;66:620-625. PubMedAbstract available
LI X, Zhang Y, Mixdorf JC, Wu Q, et al Development and Preclinical Evaluation of [(64)Cu]Cu-NOTA-ABDB6: A CD70 and
Albumin Dual-Binding Tracer with Improved Pharmacokinetics.
J Nucl Med. 2025;66:552-558. PubMedAbstract available
LI S, Abdelhafez YG, Nardo L, Cherry SR, et al Total-Body Parametric Imaging Using Relative Patlak Plot.
J Nucl Med. 2025;66:654-661. PubMedAbstract available
MILLER RJH, Kavanagh P, Lemley M, Liang JX, et al Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic
Accuracy of Myocardial Perfusion Imaging.
J Nucl Med. 2025;66:648-653. PubMedAbstract available
UDOVICICH C, Bressel M, Manji J, Ali M, et al PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma:
The Proof-of-Concept PEDESTAL Study.
J Nucl Med. 2025;66:531-536. PubMedAbstract available
March 2025
AL-IBRAHEEM A, Scott AM, Abdlkadir AS, Vrachimis A, et al Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from
Nuclear Medicine Global Initiative.
J Nucl Med. 2025 Mar 27:jnumed.124.269215. doi: 10.2967/jnumed.124.269215. PubMedAbstract available
MECKEL M, Ehrenberg S, Schmidt T, Ritt P, et al Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium
Paraaminohippurate Coadministration in a Rat Model.
J Nucl Med. 2025 Mar 27:jnumed.124.268411. doi: 10.2967/jnumed.124.268411. PubMedAbstract available
SABAHI Z, Nguyen A, Wong K, Li S, et al Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and
Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for
Metastatic Disease.
J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896. PubMedAbstract available
CHEN DC, Buteau JP, Emmett L, Alipour R, et al Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate-
to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on
[(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901. PubMedAbstract available
HERR FL, Dascalescu C, Fabritius MP, Sheikh GT, et al PET- and CT-Based Imaging Criteria for Response Assessment of
Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy.
J Nucl Med. 2025 Mar 27:jnumed.124.268621. doi: 10.2967/jnumed.124.268621. PubMedAbstract available
HINDIE E, Patel RB Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the
Underpinning Mechanisms for Future Actions.
J Nucl Med. 2025 Mar 27:jnumed.125.269644. doi: 10.2967/jnumed.125.269644. PubMed
SUN H, Cheng D, Du X, Sun C, et al A Rare Influenza B Virus-Associated Cerebellitis Detected by (18)F-FDG PET/CT
Imaging.
J Nucl Med. 2025 Mar 27:jnumed.125.269548. doi: 10.2967/jnumed.125.269548. PubMed
TANG W, Qi L, Chen M, Zhang Y, et al Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in
Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective,
Single-Center, Phase II Study.
J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189. PubMedAbstract available
BOELLAARD R, Zwezerijnen GJC, Buvat I, Champion L, et al Measuring Total Metabolic Tumor Volume from (18)F-FDG PET: A Reality Check.
J Nucl Med. 2025 Mar 13:jnumed.124.269271. doi: 10.2967/jnumed.124.269271. PubMedAbstract available
HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving
Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972. PubMedAbstract available
CONSTANTINO CS, Oliveira FPM, Machado M, Vinga S, et al The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the
Fully Automatic Segmentation of Lesions Avid for [(18)F]FDG and [(68)Ga]Ga-PSMA
in PET/CT.
J Nucl Med. 2025 Mar 13:jnumed.124.269067. doi: 10.2967/jnumed.124.269067. PubMedAbstract available
REED MB, Murgas M, Lanzenberger R, Hahn A, et al The Value of Functional PET in Quantifying Neurotransmitter Dynamics.
J Nucl Med. 2025 Mar 13:jnumed.124.269238. doi: 10.2967/jnumed.124.269238. PubMed
TUNALI I, Wang J, Arora AK, Kim MJ, et al Development and Validation of a (18)F-Flortaucipir PET Visual Stratification
Method.
J Nucl Med. 2025 Mar 13:jnumed.124.268700. doi: 10.2967/jnumed.124.268700. PubMedAbstract available
MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al Reply to "The Value of Functional PET in Quantifying Neurotransmitter Dynamics".
J Nucl Med. 2025 Mar 13:jnumed.125.269473. doi: 10.2967/jnumed.125.269473. PubMed
PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in
Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and
Metaanalysis.
J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163. PubMedAbstract available
MORAITIS A, Prochnow A, Poeppel TD, Schmitz J, et al Tumor Dose-Response Relationship of [(131)I]MIBG Therapy in Patients with Neural
Crest Tumors by Means of [(124)I]MIBG PET.
J Nucl Med. 2025 Mar 13:jnumed.124.269377. doi: 10.2967/jnumed.124.269377. PubMedAbstract available
BERNER K, Hernes E, Kvassheim M, Revheim ME, et al First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane
Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic
Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299. PubMedAbstract available
LIU S, Pan Q, Zhang H, Peng L, et al Differences in Fibroinflammatory Activity Shown on (68)Ga-FAPI-04 and (18)F-FDG
PET/CT in the Two Subtypes of IgG4-Related Disease.
J Nucl Med. 2025 Mar 6:jnumed.124.268943. doi: 10.2967/jnumed.124.268943. PubMedAbstract available
JUWEID ME, Al-Leimon O, Al-Qasem SF, Aljarah I, et al Self-Citation Among Highly Cited Nuclear Medicine and Medical Imaging
Researchers.
J Nucl Med. 2025 Mar 6:jnumed.124.269357. doi: 10.2967/jnumed.124.269357. PubMed
METSER U, Lukovic J, Mesci A, MacCrostie P, et al [(18)F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal
Canal: Results of a Prospective Multicenter Registry.
J Nucl Med. 2025 Mar 6:jnumed.124.269289. doi: 10.2967/jnumed.124.269289. PubMedAbstract available
FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate
Cancer: Biodistribution and Therapeutic Efficacy.
J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508. PubMedAbstract available
KNUUTI J, Kobylecka M, Krajewski S, Steczek L, et al Biodistribution, Safety Profile, and Radiation Dosimetry of [(18)F]SYN2, a PET
Cardiac Perfusion Tracer, in Healthy Subjects.
J Nucl Med. 2025 Mar 6:jnumed.124.268872. doi: 10.2967/jnumed.124.268872. PubMedAbstract available
IMBER BS, Yu KKH, Abida W, Pike LRG, et al Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After
Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617.
J Nucl Med. 2025 Mar 6:jnumed.124.269175. doi: 10.2967/jnumed.124.269175. PubMed
WANG R, Wang J, Xiang J, Sui H, et al Comparison of [(68)Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and
[(18)F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of
FAP-Targeted Radiopharmaceutical Therapy.
J Nucl Med. 2025 Mar 6:jnumed.124.268258. doi: 10.2967/jnumed.124.268258. PubMedAbstract available
KURKOWSKA S, Brosch-Lenz J, Dewaraja YK, Frey E, et al An International Study of Factors Affecting Variability of Dosimetry
Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses.
J Nucl Med. 2025;66:441-448. PubMedAbstract available
BODEI L, Cremonesi M, Ferrari M, Mittra ES, et al Dosimetry of [(177)Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine
Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
J Nucl Med. 2025;66:449-456. PubMedAbstract available
FU JF, Juttukonda MR, Garimella A, Salvatore AN, et al [(18)F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion:
Bias and Correlation Against [(15)O]Water.
J Nucl Med. 2025;66:410-417. PubMedAbstract available
AHMAD AA, Ghim M, Kukreja G, Neishabouri A, et al Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen
Turnover in Pulmonary Fibrosis.
J Nucl Med. 2025;66:425-433. PubMedAbstract available
GILLETT D, Senanayake R, MacFarlane J, Bashari W, et al A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of
Para-Chloro-2-[(18)F]Fluoroethyletomidate in Healthy Volunteers and Patients with
Primary Aldosteronism.
J Nucl Med. 2025;66:434-440. PubMedAbstract available
MARQUIS H, Schmidtlein CR, de Nijs R, Minguez Gabina P, et al MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution
Characterization and Shape-Specific Partial-Volume Correction.
J Nucl Med. 2025;66:457-465. PubMedAbstract available
February 2025
MURTHY V, Ludwig V, Gafita A, Hope TA, et al The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted
Radiopharmaceutical Therapy.
J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818. PubMedAbstract available
MENCH A, Winters C, Mittra E, Szidonya L, et al Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed
Workflow and Essential Guidelines for Nonspecialists.
J Nucl Med. 2025 Feb 27:jnumed.124.268522. doi: 10.2967/jnumed.124.268522. PubMedAbstract available
WANG J, Lan X, Shi H, Li S, et al A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine
Conducted by the Chinese Society of Nuclear Medicine.
J Nucl Med. 2025 Feb 27:jnumed.124.269044. doi: 10.2967/jnumed.124.269044. PubMed
CONSTANZO J, Parach A, David T, Karam J, et al MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of
Radiopharmaceutical Therapy.
J Nucl Med. 2025 Feb 27:jnumed.124.268857. doi: 10.2967/jnumed.124.268857. PubMedAbstract available
TURCO F, Gillessen S, Herrmann K, Paone G, et al Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical
Therapy.
J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730. PubMedAbstract available
VERA P, Giraud P, Hapdey S, Gouel P, et al Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of
Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung
Cancer.
J Nucl Med. 2025 Feb 27:jnumed.124.268499. doi: 10.2967/jnumed.124.268499. PubMedAbstract available
GAJECKI L, Lebedeva IV, Liao YR, Ambriz D, et al IL13Ralpha2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
J Nucl Med. 2025 Feb 20:jnumed.124.268762. doi: 10.2967/jnumed.124.268762. PubMedAbstract available
CHEVALEYRE C, Zimmermann L, Specklin S, Kereselidze D, et al PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of
Combined Anti-PD-L1 Immunotherapy and Targeted Therapy.
J Nucl Med. 2025 Feb 20:jnumed.124.268586. doi: 10.2967/jnumed.124.268586. PubMedAbstract available
VIERING O, Holzleitner N, Claus R, Amerein A, et al CCK(2) Receptor Ligand [(68)Ga]Ga-DOTA-CCK-66 PET/CT Outperforms
[(68)Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer.
J Nucl Med. 2025 Feb 20:jnumed.124.269201. doi: 10.2967/jnumed.124.269201. PubMed
VAN RIJSEWIJK ND, Lanz P, Wouthuyzen-Bakker M, Glaudemans AWJM, et al Evaluating Bone Healing with [(18)F]NaF PET/CT During Bone Segment Transport in
Femoral Fracture Treatment.
J Nucl Med. 2025 Feb 20:jnumed.124.268913. doi: 10.2967/jnumed.124.268913. PubMed
BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against
Nectin-4-Positive Triple-Negative Breast Cancer.
J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387. PubMedAbstract available
SANTORO-FERNANDES V, Schott B, Weisman AJ, Lokre O, et al Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor
Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.
J Nucl Med. 2025 Feb 13:jnumed.124.267809. doi: 10.2967/jnumed.124.267809. PubMedAbstract available
MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al (176)Lu Radiation Dose of Long-Axial Field of View PET Scanners.
J Nucl Med. 2025 Feb 13:jnumed.124.269187. doi: 10.2967/jnumed.124.269187. PubMed
YU S, Yang Z, Ding Z, Jia Y, et al (68)Ga-FAPI-04 PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in
Lupus Nephritis.
J Nucl Med. 2025 Feb 13:jnumed.124.268643. doi: 10.2967/jnumed.124.268643. PubMedAbstract available
SUN Y, Hao Z, Gao H, Yang G, et al [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to
Pilot Clinical Study.
J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564. PubMedAbstract available
YUSUFALY T, Roncali E, Brosch-Lenz J, Uribe C, et al Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies:
Current Tools, Techniques, and Uncharted Territories.
J Nucl Med. 2025 Feb 13:jnumed.124.267927. doi: 10.2967/jnumed.124.267927. PubMedAbstract available
BABICH J, Kostakoglu L New Approaches in Radiopharmaceutical Development: John Babich Talks with Lale
Kostakoglu About Current and Coming Trends in Diagnostics and Therapeutics.
J Nucl Med. 2025 Feb 13:jnumed.125.269492. doi: 10.2967/jnumed.125.269492. PubMed
SUN L, Sun Y, Zuo K, Fan L, et al Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in
Triple-Negative Breast Cancer from Bench to First-in-Human.
J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024. PubMedAbstract available
CZERNIN J, Bodei L, Modlin I, Calais J, et al Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical
Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
J Nucl Med. 2025 Feb 6:jnumed.124.269401. doi: 10.2967/jnumed.124.269401. PubMed
LASSEN ML, Kertesz H, Rausch I, Panin V, et al Positron Range Correction Helps Enhance the Image Quality of Cardiac (82)Rb
PET/CT.
J Nucl Med. 2025 Feb 6:jnumed.124.267855. doi: 10.2967/jnumed.124.267855. PubMedAbstract available
MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their
Prognostic Value in Radical Prostatectomy.
J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719. PubMedAbstract available
DERLIN T, Widjaja L, Harke NN, Czerner C, et al (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in
Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319. PubMedAbstract available
VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate
Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340. PubMedAbstract available
GHEYSENS O, Pelletier-Galarneau M, Treglia G, Israel O, et al Summary: EANM/SNMMI Release Joint Guideline/Procedure Standard for [(18)F]FDG
Hybrid PET Use in Infection and Inflammation in Adults, Version 2.0.
J Nucl Med. 2025 Feb 6:jnumed.125.269538. doi: 10.2967/jnumed.125.269538. PubMed
LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in
Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318. PubMedAbstract available
OGATA A, Ikenuma H, Yasuno F, Nihashi T, et al First-in-Human Study of [(11)C]NCGG401 for Imaging Colony-Stimulating Factor 1
Receptors in the Brain.
J Nucl Med. 2025;66:302-308. PubMedAbstract available
OLAFSON E, Tonietto M, Klein G, Teng E, et al In Vivo Head-to-Head Comparison of [(18)F]GTP1 with [(18)F]MK-6240 and
[(18)F]PI-2620 in Alzheimer Disease.
J Nucl Med. 2025;66:277-285. PubMedAbstract available
SONG Y, Lee JH, Kim HK, Lee JH, et al Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson
Disease.
J Nucl Med. 2025;66:286-292. PubMedAbstract available
OH M, Brumberg J, Sossi V, Varrone A, et al Preserved Serotonin Transporter Availability in Parkinson Disease Measured with
Either [(11)C]MADAM or [(11)C]DASB: A Study Including 2 Separate Cohorts of
Nondepressed Patients.
J Nucl Med. 2025;66:309-314. PubMedAbstract available
January 2025
WANG X, Dong Y, Zhang S China's Innovations in Nuclear Medicine: Global Insights into Clinical
Advancements and Impact.
J Nucl Med. 2025 Jan 30:jnumed.124.269185. doi: 10.2967/jnumed.124.269185. PubMed
MIEDERER I, Buchholz HG, Rademacher L, Eckart C, et al Dopaminergic Mechanisms of Cognitive Flexibility: An [(18)F]Fallypride PET Study.
J Nucl Med. 2025 Jan 30:jnumed.124.268317. doi: 10.2967/jnumed.124.268317. PubMedAbstract available
ULANER GA, Lewis J, Landgren O CD38-Targeted (89)Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting
Clinical Care.
J Nucl Med. 2025 Jan 30:jnumed.124.269393. doi: 10.2967/jnumed.124.269393. PubMed
STRIGARI L, Schwarz J, Bradshaw T, Brosch-Lenz J, et al Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies:
Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins.
J Nucl Med. 2025 Jan 23:jnumed.124.268186. doi: 10.2967/jnumed.124.268186. PubMedAbstract available
VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic
Factor for Endocrine Therapy Response and Survival in Patients with Estrogen
Receptor-Positive Metastatic Breast Cancer.
J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984. PubMedAbstract available
WANG R, Huang M, Wang W, Li M, et al Preclinical Evaluation of (68)Ga/(177)Lu-Labeled FAP-Targeted Peptide for Tumor
Radiopharmaceutical Imaging and Therapy.
J Nucl Med. 2025 Jan 23:jnumed.124.268689. doi: 10.2967/jnumed.124.268689. PubMedAbstract available
LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence
Detection After Prostatectomy: A Prospective Phase II Trial.
J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574. PubMedAbstract available
YAN X, Noergaard M, Morse CL, Liow JS, et al PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker
of Neuroinflammation.
J Nucl Med. 2025 Jan 23:jnumed.124.268525. doi: 10.2967/jnumed.124.268525. PubMedAbstract available
VEIT-HAIBACH P, Herrmann K, Zimmermann R, Hustinx R, et al Green Nuclear Medicine and Radiotheranostics.
J Nucl Med. 2025 Jan 23:jnumed.124.268928. doi: 10.2967/jnumed.124.268928. PubMedAbstract available
BAILEY DL, Willowson KP, O'Keefe G, Goodman S, et al A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging
Trials Using Novel Radionuclides.
J Nucl Med. 2025 Jan 16:jnumed.124.268578. doi: 10.2967/jnumed.124.268578. PubMedAbstract available
ENKE JS, Reitsam NG, Dintner S, Liesche-Starnecker F, et al Comprehensive Characterization via Molecular Imaging, Longitudinal Multisite
Sampling, and Autoptic Work-up in Advanced Small Cell Lung Cancer Undergoing
SSTR-Directed Radiopharmaceutical Therapy.
J Nucl Med. 2025 Jan 16:jnumed.124.268513. doi: 10.2967/jnumed.124.268513. PubMedAbstract available
BARBRY F, Chevalier B, Beron A, Lion G, et al Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid
Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I
Posttreatment Scanning.
J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539. PubMed
CERIANI L, Milan L, Pirosa MC, Martelli M, et al PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A
Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial
Patient Cohort.
J Nucl Med. 2025 Jan 16:jnumed.124.268874. doi: 10.2967/jnumed.124.268874. PubMedAbstract available
PRASAD N, Harris E, DeFilippis EM, Sayer G, et al PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft
Vasculopathy Progression and Clinical Outcomes.
J Nucl Med. 2025 Jan 16:jnumed.124.268713. doi: 10.2967/jnumed.124.268713. PubMedAbstract available
GAO M, Daube-Witherspoon ME, Karp JS, Surti S, et al Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion
Quantification and Detectability.
J Nucl Med. 2025 Jan 16:jnumed.124.267769. doi: 10.2967/jnumed.124.267769. PubMedAbstract available
LANGEN KJ, Stoffels G, Filss CP, Kocher M, et al Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with
Suspected Glioma Relapse: Role in Clinical Practice.
J Nucl Med. 2025 Jan 16:jnumed.124.268768. doi: 10.2967/jnumed.124.268768. PubMedAbstract available
RAMOS-TORRES KM, Conti S, Zhou YP, Tiss A, et al Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer
[(18)F]3F4AP.
J Nucl Med. 2025 Jan 16:jnumed.124.268242. doi: 10.2967/jnumed.124.268242. PubMedAbstract available
VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled
Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer
and Other Neuroendocrine Tumors.
J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877. PubMedAbstract available
VRAKA C, Homolya M, Ozer O, Spittler A, et al RadioFlow Cytometry Reveals That [(18)F]FDG Uptake in K-RAS Lung Cancer Is Driven
by Immune Cells: An Analysis on a Single-Cell Level.
J Nucl Med. 2025 Jan 16:jnumed.124.268799. doi: 10.2967/jnumed.124.268799. PubMedAbstract available
RABINOVICI GD, Knopman DS, Arbizu J, Benzinger TLS, et al Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the
Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging
Workgroup.
J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756. PubMedAbstract available
MADSEN C, Fuglo D, Pedersen M, Broholm R, et al Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for
Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate
Cancer.
J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275. PubMedAbstract available
MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a
National Health Care System.
J Nucl Med. 2025;66:75-83. PubMedAbstract available
UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer:
From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
J Nucl Med. 2025;66:54-60. PubMedAbstract available
MILLER RJH, Patel KK, Kwiecinski J, Slipczuk L, et al Nuclear Cardiology Surrogate Biomarkers in Clinical Trials.
J Nucl Med. 2025;66:4-11. PubMedAbstract available
HOU P, Chen H, Liang S, Guo W, et al Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic
Remodeling in Pulmonary Arterial Hypertension.
J Nucl Med. 2025;66:98-103. PubMedAbstract available
BARTEL T 2024 SNMMI Highlights Lecture: General Clinical Specialties.
J Nucl Med. 2025;66:158-161. PubMedAbstract available
MICHNO M, Schmitz J, Foerges AL, Beer S, et al Effect of Acute Hypoxia Exposure on the Availability of A(1) Adenosine Receptors
and Perfusion in the Human Brain.
J Nucl Med. 2025;66:142-149. PubMedAbstract available
OMIDVARI N, Shanina E, Leung EK, Sun X, et al Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging
Applications: Moving Beyond Standard Evaluations.
J Nucl Med. 2025;66:150-157. PubMedAbstract available
PARIHAR AS, Mhlanga JC, Royal HD, Siegel BA, et al Comparability of Quantifying Relative Lung Ventilation with Inhaled
(99m)Tc-Technegas and (133)Xe in Patients Undergoing Evaluation for Lung
Transplantation.
J Nucl Med. 2025;66:104-109. PubMedAbstract available
GHAZANFARI N, Liow JS, Kim MJ, Cureton R, et al [(11)C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to
Cyclooxygenase-1 in the Human Brain.
J Nucl Med. 2025;66:117-122. PubMedAbstract available
SCHWEIGER L, Maurer T, Simon R, Horn T, et al Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided
Surgery.
J Nucl Med. 2025;66:67-72. PubMedAbstract available
GOTO T, Kikuchi S, Sakurai Y, Tsuruta Y, et al Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in
Patients with Chronotropic Incompetence Without Heart Failure.
J Nucl Med. 2025 Jan 2:jnumed.124.268638. doi: 10.2967/jnumed.124.268638. PubMedAbstract available
EMMETT L SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes
with Theranostics Therapy.
J Nucl Med. 2025 Jan 2:jnumed.124.268325. doi: 10.2967/jnumed.124.268325. PubMed
December 2024
CHENG K, Ge L, Song M, Li W, et al Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for
Noninvasive Monitoring Early Responses of Immunotherapy.
J Nucl Med. 2024 Dec 12:jnumed.124.268068. doi: 10.2967/jnumed.124.268068. PubMedAbstract available
ROUSSEAU JA, Maier M, Ait-Mohand S, Dumulon-Perreault V, et al Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic
Lateral Sclerosis Mouse Model.
J Nucl Med. 2024 Dec 12:jnumed.124.268343. doi: 10.2967/jnumed.124.268343. PubMedAbstract available
WEEKS JK, Pantel AR, Gitto SB, Liu F, et al [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET,
Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627. PubMedAbstract available
VAN DER WEIJDEN CWJ, Ahmed AKMA, van der Hoorn A, Zhu J, et al Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple
Sclerosis Using [(11)C]MeDAS PET: A Translational Study.
J Nucl Med. 2024 Dec 5:jnumed.123.266896. doi: 10.2967/jnumed.123.266896. PubMedAbstract available
CUTLER CS A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics.
J Nucl Med. 2024;65:7A-8A. PubMed
VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor
Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large
B-Cell Lymphoma.
J Nucl Med. 2024;65:1876-1883. PubMedAbstract available
MICHALSKI K, Kosmala A, Hartrampf PE, Heinrich M, et al [(18)F]FDG and [(68)Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in
Patients with High-Grade Neuroendocrine Neoplasms.
J Nucl Med. 2024;65:1899-1903. PubMedAbstract available
November 2024
HOPE TA, Calais J, Goenka AH, Haberkorn U, et al SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation
Protein (FAP) PET.
J Nucl Med. 2024 Nov 21:jnumed.124.269002. doi: 10.2967/jnumed.124.269002. PubMed
JACENE H, Czernin J Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About
Leadership in Clinical Nuclear Medicine and the SNMMI.
J Nucl Med. 2024 Nov 21:jnumed.124.269029. doi: 10.2967/jnumed.124.269029. PubMed
ERMIS E, Bachmann N, Lutz K, Pyka T, et al Meningioma Revisited: Should Whole-Body Staging with [(68)Ga]Ga-DOTATOC PET/CT of
High-Grade Meningiomas Become Standard Practice?
J Nucl Med. 2024 Nov 21:jnumed.124.267934. doi: 10.2967/jnumed.124.267934. PubMed
DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with
Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617:
Importance of (18)F-FDG-Avid Discordant Findings.
J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167. PubMedAbstract available
WENZEL M, Koll F, Hoeh B, Humke C, et al Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical
Therapy in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807. PubMedAbstract available
COLLIJ LE, Bischof GN, Altomare D, Bader I, et al Quantification Supports Amyloid PET Visual Assessment of Challenging Cases:
Results from the AMYPAD Diagnostic and Patient Management Study.
J Nucl Med. 2024 Nov 14:jnumed.124.268119. doi: 10.2967/jnumed.124.268119. PubMedAbstract available
LOU K, Wang J, He H, Wang Y, et al Value of [(68)Ga]Ga-NYM046 PET/CT, in Comparison with (18)F-FDG PET/CT, for
Diagnosis of Clear Cell Renal Cell Carcinoma.
J Nucl Med. 2024 Nov 14:jnumed.124.267527. doi: 10.2967/jnumed.124.267527. PubMedAbstract available
HUANG W, Cao M, Wu Y, Zhang Y, et al Immuno-PET/CT Imaging of Trop2 with [(18)F]AlF-RESCA-T4 Differentiates Lung
Cancer from Inflammation.
J Nucl Med. 2024 Nov 14:jnumed.124.268751. doi: 10.2967/jnumed.124.268751. PubMedAbstract available
DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al SPECT/CT in Early Response Assessment of Patients with Metastatic
Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665. PubMedAbstract available
ZHANG H, Ren C, Liu Y, Yan X, et al Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI
Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards.
J Nucl Med. 2024 Nov 7:jnumed.124.267963. doi: 10.2967/jnumed.124.267963. PubMedAbstract available
ZHOU X, Wu Q, Zhai W, Zhang Y, et al CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A
Translational Study.
J Nucl Med. 2024 Nov 7:jnumed.124.268509. doi: 10.2967/jnumed.124.268509. PubMedAbstract available
KONIAR H, Wharton L, Ingham A, Morales Oliver AP, et al Preclinical Evaluation of (226)Ac as a Theranostic Agent: Imaging, Dosimetry, and
Therapy.
J Nucl Med. 2024;65:1762-1768. PubMedAbstract available
October 2024
SONNI I, Weiner AB, Doddipalli S, Deol M, et al Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer
Detection by PSMA PET/CT and Multiparametric MRI.
J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443. PubMedAbstract available
YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose)
Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254. PubMedAbstract available
HUANG RR, Zuo C, Mona CE, Holzgreve A, et al FAP and PSMA Expression by Immunohistochemistry and PET Imaging in
Castration-Resistant Prostate Cancer: A Translational Pilot Study.
J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037. PubMedAbstract available
SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy
PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant
Prostate Cancer.
J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606. PubMedAbstract available
HELISCH A, Kratochwil C, Kleist C, Kramer S, et al Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated
Radiopharmaceutical Therapy with (213)Bi-FAPI-46: Pilot Experience in Patients
with End-Stage, Progressive Metastatic Tumors.
J Nucl Med. 2024 Oct 30:jnumed.124.268386. doi: 10.2967/jnumed.124.268386. PubMedAbstract available
WANG R, Kang W, Liu Z, Zheng Y, et al Head-to-Head Comparison of [(68)Ga]Ga-NOTA-RM26 and [(18)F]FDG PET/CT in Patients
with Gastrointestinal Stromal Tumors: A Prospective Study.
J Nucl Med. 2024 Oct 24:jnumed.124.267810. doi: 10.2967/jnumed.124.267810. PubMedAbstract available
MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions
Change During the Scan?
J Nucl Med. 2024 Oct 24:jnumed.124.267494. doi: 10.2967/jnumed.124.267494. PubMedAbstract available
KATUGAMPOLA S, Wang J, Howell RW MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate
Optimized Radiopharmaceutical Cocktails for Therapy.
J Nucl Med. 2024 Oct 24:jnumed.123.267238. doi: 10.2967/jnumed.123.267238. PubMedAbstract available
LEVI J, Das M, Vasanawala MS, Behl D, et al [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients
with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
J Nucl Med. 2024 Oct 24:jnumed.124.268253. doi: 10.2967/jnumed.124.268253. PubMedAbstract available
AMEREIN A, Maurer C, Kircher M, Gable A, et al Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients
with Advanced Meningioma: Initial Safety and Efficacy.
J Nucl Med. 2024 Oct 24:jnumed.124.268217. doi: 10.2967/jnumed.124.268217. PubMedAbstract available
BOSS M, Eriksson O, Mikkola K, Eek A, et al Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT.
J Nucl Med. 2024 Oct 17:jnumed.124.268158. doi: 10.2967/jnumed.124.268158. PubMedAbstract available
ARBIZU J, Morbelli S, Minoshima S, Barthel H, et al SNMMI Procedure Standard/EANM Practice Guideline for Brain [(18)F]FDG PET
Imaging, Version 2.0.
J Nucl Med. 2024 Oct 17:jnumed.124.268754. doi: 10.2967/jnumed.124.268754. PubMedAbstract available
JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly
Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065. PubMedAbstract available
LIU Q, Xu X, Yang Z, Zhang J, et al Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric
Cancer.
J Nucl Med. 2024 Oct 10:jnumed.124.267529. doi: 10.2967/jnumed.124.267529. PubMedAbstract available
GAFITA A, Menard AR, Solnes LB Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient
Care.
J Nucl Med. 2024 Oct 10:jnumed.124.268608. doi: 10.2967/jnumed.124.268608. PubMed
HOTTA M, Kim GHJ, Rerkpichaisuth V, Teng PY, et al Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from
Patients with Advanced Interstitial Lung Disease.
J Nucl Med. 2024 Oct 3:jnumed.124.268351. doi: 10.2967/jnumed.124.268351. PubMedAbstract available
PELLETIER-GALARNEAU M, Simard F, Tadros R, Tremblay-Gravel M, et al Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?
J Nucl Med. 2024 Oct 3:jnumed.124.268033. doi: 10.2967/jnumed.124.268033. PubMed
PRATT EC, Mezzadra R, Kulick A, Kaminsky S, et al uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.
J Nucl Med. 2024 Oct 3:jnumed.124.268278. doi: 10.2967/jnumed.124.268278. PubMedAbstract available
FERRANDEZ MC, Golla SSV, Eertink JJ, Wiegers SE, et al Validation of an Artificial Intelligence-Based Prediction Model Using 5 External
PET/CT Datasets of Diffuse Large B-Cell Lymphoma.
J Nucl Med. 2024 Oct 3:jnumed.124.268191. doi: 10.2967/jnumed.124.268191. PubMedAbstract available
CARLSEN EA, Loft M, Johnbeck CB, Knigge U, et al Routine Use of [(64)Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center:
Referral Patterns and Image Results of 2,249 Consecutive Scans.
J Nucl Med. 2024 Oct 3:jnumed.124.267939. doi: 10.2967/jnumed.124.267939. PubMedAbstract available
CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical
Therapy.
J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363. PubMedAbstract available
LEE H, Alhamshari AS, Patel V, Bhattaru A, et al Cardiac Neuroendocrine Tumor Metastases on (68)Ga-DOTATATE PET/CT: Identification
and Prognostic Significance.
J Nucl Med. 2024 Oct 3:jnumed.124.267948. doi: 10.2967/jnumed.124.267948. PubMedAbstract available
MILLER RJH, Lemley M, Shanbhag A, Ramirez G, et al The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation
SPECT (REFINE SPECT 2.0).
J Nucl Med. 2024 Oct 3:jnumed.124.268292. doi: 10.2967/jnumed.124.268292. PubMedAbstract available
PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as
Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256. PubMed
RYU J, Hyung J, Han S, Jeong JH, et al Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent
or Metastatic Breast Cancer.
J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913. PubMedAbstract available
ZHANG X, Lin Z, Feng Y, Lin Z, et al Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with
[(68)Ga]Ga-FAPI-04 PET, [(18)F]FDG PET, and Contrast-Enhanced MRI:
Lesion-to-Lesion Comparison with Pathology.
J Nucl Med. 2024;65:1548-1556. PubMedAbstract available
VAN SLUIS J, van Snick JH, Glaudemans AWJM, Slart RHJA, et al Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET.
J Nucl Med. 2024;65:1652-1657. PubMedAbstract available
ENKE JS, Ritzel K, Asbach E, Reitsam NG, et al C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using
[(99m)Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
J Nucl Med. 2024;65:1640-1644. PubMedAbstract available
ROOHANI B, Mendez AS, Dangarwala M, Katz S, et al Nuclear Imaging of Bispecific Antibodies on the Rise.
J Nucl Med. 2024;65:1512-1517. PubMedAbstract available
September 2024
DONG Y, Wang Z, Hu X, Sun Y, et al [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable
Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy:
A Phase II Clinical Trial.
J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557. PubMedAbstract available
BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific
Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After
Radical Prostatectomy: A Prospective Single-Center Study.
J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877. PubMedAbstract available
POULIOT F, Saad F, Rousseau E, Richard PO, et al Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET
Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020. PubMedAbstract available
PALESTRO CJ, Abikhzer G, Bar-Sever Z, Bartel T, et al Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of
Unknown Origin.
J Nucl Med. 2024 Sep 26:jnumed.124.268797. doi: 10.2967/jnumed.124.268797. PubMedAbstract available
BYUN JW, Paeng JC, Kim YJ, Lee SP, et al Evaluation of Fibroblast Activation Protein Expression Using (68)Ga-FAPI46 PET in
Hypertension-Induced Tissue Changes.
J Nucl Med. 2024 Sep 26:jnumed.124.267489. doi: 10.2967/jnumed.124.267489. PubMedAbstract available
JADVAR H, Iravani A, Bodei L, Calais J, et al Challenges with (177)Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical
Practice.
J Nucl Med. 2024 Sep 19:jnumed.124.268023. doi: 10.2967/jnumed.124.268023. PubMed
YOUNG JJ, O'Dell RS, Naganawa M, Toyonaga T, et al Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to
Assess Synaptic Density Alterations in Alzheimer Disease with [(11)C]UCB-J PET.
J Nucl Med. 2024 Sep 19:jnumed.124.267419. doi: 10.2967/jnumed.124.267419. PubMedAbstract available
TUNCER O, Steinberger D, Steiner J, Hinojos M, et al Quantitative SPECT/CT Metrics in Early Prediction of [(177)Lu]Lu-DOTATATE
Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients.
J Nucl Med. 2024 Sep 12:jnumed.124.267964. doi: 10.2967/jnumed.124.267964. PubMedAbstract available
POOT AJ, Lapa C, Weber WA, Lam MGEH, et al [(68)Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for
Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series.
J Nucl Med. 2024 Sep 12:jnumed.124.268147. doi: 10.2967/jnumed.124.268147. PubMedAbstract available
METSER U, Nunez JE, Chan D, Kulanthaivelu R, et al Dual Somatostatin Receptor/(18)F-FDG PET/CT Imaging in Patients with
Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med. 2024 Sep 12:jnumed.124.267982. doi: 10.2967/jnumed.124.267982. PubMedAbstract available
AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell
Carcinoma: A Systematic Review and Metaanalysis.
J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049. PubMedAbstract available
ALAKONYA H, Koustoulidou S, Hopkins SL, Veal M, et al Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody
TAT Conjugate with SPECT.
J Nucl Med. 2024 Sep 12:jnumed.124.267736. doi: 10.2967/jnumed.124.267736. PubMedAbstract available
GALBIATI A, Bocci M, Ravazza D, Mock J, et al Preclinical Evaluation of (177)Lu-OncoFAP-23, a Multivalent FAP-Targeted
Radiopharmaceutical Therapeutic for Solid Tumors.
J Nucl Med. 2024 Sep 12:jnumed.124.268200. doi: 10.2967/jnumed.124.268200. PubMedAbstract available
POTY S, Ordas L, Dekempeneer Y, Parach AA, et al Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using
Pretargeting.
J Nucl Med. 2024 Sep 12:jnumed.124.267624. doi: 10.2967/jnumed.124.267624. PubMedAbstract available
WRAY R, Mauguen A, Michaud L, Leithner D, et al Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation
Criteria and Validation of Interreader Reliability, Reproducibility, and
Performance.
J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775. PubMedAbstract available
SULLIVAN R, Hou J, Yu L, Wilk B, et al Design, Synthesis, and Preclinical Evaluation of a High-Affinity (18)F-Labeled
Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After
Myocardial Infarction.
J Nucl Med. 2024 Sep 12:jnumed.124.267578. doi: 10.2967/jnumed.124.267578. PubMedAbstract available
SIVAKUMARAN T, Cardin A, Callahan J, Wong HL, et al Evaluating the Utility of (18)F-FDG PET/CT in Cancer of Unknown Primary.
J Nucl Med. 2024 Sep 5:jnumed.123.267274. doi: 10.2967/jnumed.123.267274. PubMedAbstract available
EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and
-Positive Metastatic Breast Cancer.
J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636. PubMedAbstract available
BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive
Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751. PubMedAbstract available
KULKARNI HR, Maupin KA, Brennan T, Forsberg J, et al First-in-Human Total-Body PET/CT Imaging Using (89)Zr-Labeled MUC5AC Antibody in
a Patient with Pancreatic Adenocarcinoma.
J Nucl Med. 2024 Sep 5:jnumed.124.268074. doi: 10.2967/jnumed.124.268074. PubMed
Robert Carretta, MD, 1941-2023.
J Nucl Med. 2024;65:1498. PubMed
BEHRENBRUCH C FINDing the Future of Radiopharma.
J Nucl Med. 2024;65:1333-1335. PubMed
August 2024
KIM D, Kang SK, Shin SA, Choi H, et al Improving (18)F-FDG PET Quantification Through a Spatial Normalization Method.
J Nucl Med. 2024 Aug 29:jnumed.123.267360. doi: 10.2967/jnumed.123.267360. PubMedAbstract available
MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast
Cancer Patients at a Tertiary Referral Hospital in Kenya.
J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851. PubMedAbstract available
THIN P, Hotta M, Gafita A, Grogan T, et al Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in
Patients with Recurrent Prostate Cancer Under Observation After a Negative
(68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591. PubMedAbstract available
HO KV, Tatum DS, Watkinson L, Carmack T, et al Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu
Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667. PubMedAbstract available
INCE S, Laforest R, Itani M, Prasad V, et al Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT
Population: Which Metric Minimizes Tracer Uptake Time Dependence?
J Nucl Med. 2024 Aug 14:jnumed.123.266469. doi: 10.2967/jnumed.123.266469. PubMedAbstract available
PANDIT-TASKAR N, Zanzonico PB, Grkovski M, Donzelli M, et al Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in
Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion
Dosimetry.
J Nucl Med. 2024 Aug 14:jnumed.123.266365. doi: 10.2967/jnumed.123.266365. PubMedAbstract available
MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic
Performance of Available Standardized Criteria.
J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899. PubMedAbstract available
YADAV S, Lowery B, Tuchayi AM, Jiang F, et al Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617
Radiopharmaceutical Therapy.
J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955. PubMedAbstract available
OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate
Cancer: Incidence and Etiology.
J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772. PubMedAbstract available
LI S, Nguyen A, Counter W, John NC, et al Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically
Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11
PET/CT.
J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881. PubMedAbstract available
BOELLAARD R, Buvat I, Nioche C, Ceriani L, et al International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline
(18)F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical
Implementation.
J Nucl Med. 2024 Aug 1:jnumed.124.267789. doi: 10.2967/jnumed.124.267789. PubMedAbstract available
NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed
Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922. PubMedAbstract available
RIETBERGEN DDD, Buckle T, Slof LJ, van Meerbeek MP, et al hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery.
J Nucl Med. 2024;65:1301-1306. PubMedAbstract available
SCHELBERT H, Schoder H, Czernin J Illuminating Cardiac Function: Heinz Schelbert Talks with Heiko Schoder and
Johannes Czernin About a Pioneering Career in Nuclear Cardiology.
J Nucl Med. 2024;65:1163-1165. PubMed
RESCH S, Ziegler SI, Sheikh G, Unterrainer LM, et al Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of
Single-Time-Point Dosimetry for [(177)Lu]Lu-PSMA-I&T Therapy.
J Nucl Med. 2024;65:1272-1278. PubMedAbstract available
ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with
HOXB13 Expression.
J Nucl Med. 2024;65:1210-1216. PubMedAbstract available
CAPTIER N, Orlhac F, Hovhannisyan-Baghdasarian N, Luporsi M, et al RadShap: An Explanation Tool for Highlighting the Contributions of Multiple
Regions of Interest to the Prediction of Radiomic Models.
J Nucl Med. 2024;65:1307-1312. PubMedAbstract available
LUDWIG V, Maliha PG, Shen J, Tonnelet D, et al [(68)Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous
Germ Cell Tumor Metastatic Lesions.
J Nucl Med. 2024;65:1328-1329. PubMed
July 2024
BUDDENKOTTE T, Buchert R Unrealistic Data Augmentation Improves the Robustness of Deep Learning-Based
Classification of Dopamine Transporter SPECT Against Variability Between Sites
and Between Cameras.
J Nucl Med. 2024 Jul 25:jnumed.124.267570. doi: 10.2967/jnumed.124.267570. PubMedAbstract available
PICCARDO A, Bottoni G, Puppo C, Massollo M, et al Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder
Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT.
J Nucl Med. 2024 Jul 25:jnumed.124.267474. doi: 10.2967/jnumed.124.267474. PubMedAbstract available
GEBRE RK, Rial AM, Raghavan S, Wiste HJ, et al Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning:
Introducing THETA, a Novel Tau Summary Measure.
J Nucl Med. 2024 Jul 25:jnumed.123.267273. doi: 10.2967/jnumed.123.267273. PubMedAbstract available
PIROZZI MA, Gaudieri V, Prinster A, Magliulo M, et al StepBrain: A 3-Dimensionally Printed Multicompartmental Anthropomorphic Brain
Phantom to Simulate PET Activity Distributions.
J Nucl Med. 2024 Jul 18:jnumed.123.267277. doi: 10.2967/jnumed.123.267277. PubMedAbstract available
BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to
First-in-Human Imaging.
J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126. PubMedAbstract available
KANG F, Xie Z, Ma W, Quan Z, et al Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm
on the uMI Panorama PET/CT System.
J Nucl Med. 2024 Jul 11:jnumed.124.267446. doi: 10.2967/jnumed.124.267446. PubMedAbstract available
LARIVE T, Boursier C, Claudin M, Varlot J, et al Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET
Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis.
J Nucl Med. 2024 Jul 11:jnumed.123.267219. doi: 10.2967/jnumed.123.267219. PubMedAbstract available
CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to
Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391. PubMedAbstract available
KESSLER L, Schwaning F, Metzenmacher M, Pabst K, et al Fibroblast Activation Protein-Directed Imaging Outperforms (18)F-FDG PET/CT in
Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
J Nucl Med. 2024 Jul 3:jnumed.124.267473. doi: 10.2967/jnumed.124.267473. PubMedAbstract available
OSTER C, Kessler L, Blau T, Keyvani K, et al The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A
Comparison of Tissue, (68)Ga-FAPI-46 PET Data, and Survival Data.
J Nucl Med. 2024 Jul 3:jnumed.123.267151. doi: 10.2967/jnumed.123.267151. PubMedAbstract available
BORGWARDT L, Brok J, Andersen KF, Madsen J, et al Performing [(18)F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or
General Anesthesia for Imaging of Children with Neuroblastoma.
J Nucl Med. 2024 Jul 3:jnumed.123.267256. doi: 10.2967/jnumed.123.267256. PubMedAbstract available
ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients
with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452. PubMedAbstract available
LU Z, Polan DF, Wei L, Aryal MP, et al PET/CT-Based Absorbed Dose Maps in (90)Y Selective Internal Radiation Therapy
Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI.
J Nucl Med. 2024 Jul 3:jnumed.124.267421. doi: 10.2967/jnumed.124.267421. PubMedAbstract available
WARFVINGE CF, Gustafsson J, Roth D, Tennvall J, et al Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated
with [(177)Lu]Lu-DOTATATE.
J Nucl Med. 2024;65:1070-1075. PubMedAbstract available
June 2024
COMBET-CURT V, Buchalet C, Malicot KL, Lemanski C, et al Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous
Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort
FFCD-ANABASE.
J Nucl Med. 2024 Jun 27:jnumed.124.267626. doi: 10.2967/jnumed.124.267626. PubMedAbstract available
BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in
Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy
(the PRECISE-MDT Study).
J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586. PubMedAbstract available
LAVERDIERE I, Matte G, Darveau M, Beauregard JM, et al Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of
Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
J Nucl Med. 2024 Jun 21:jnumed.124.267603. doi: 10.2967/jnumed.124.267603. PubMed
LI H, Badawi RD, Cherry SR, Fontaine K, et al Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain
PET/CT Imager.
J Nucl Med. 2024 Jun 13:jnumed.124.267767. doi: 10.2967/jnumed.124.267767. PubMedAbstract available
MONASTERO F, Vetrone L, Cardisciani L, Renzulli M, et al [(68)Ga]Ga-PSMA-11 PET/CT-Positive Hepatic Inflammatory Pseudotumor: Possible
PSMA-Avid Pitfall in Nuclear Imaging.
J Nucl Med. 2024 Jun 13:jnumed.124.267518. doi: 10.2967/jnumed.124.267518. PubMed
FONSECA CABRERA GO, Ma X, Lin W, Zhang T, et al Synthesis of (64)Cu-, (55)Co-, and (68)Ga-Labeled Radiopharmaceuticals Targeting
Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using
Multiamine Macrocycles.
J Nucl Med. 2024 Jun 13:jnumed.124.267469. doi: 10.2967/jnumed.124.267469. PubMedAbstract available
MUKKAMALA R, Carlson DJ, Miller NK, Lindeman SD, et al Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy
with High Tumor-to-Healthy-Tissue Ratios.
J Nucl Med. 2024 Jun 13:jnumed.124.267756. doi: 10.2967/jnumed.124.267756. PubMedAbstract available
KUO PH, Esposito G, Ulaner GA, Yoo D, et al Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image
Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer:
Data from Two Phase 3 Prospective Multicenter Studies.
J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306. PubMedAbstract available
PHAM TT, Chenoweth A, Patel N, Banu A, et al In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating
Effects of a Therapeutic Antibody.
J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876. PubMedAbstract available
EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline
PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk
Prostate Cancer.
J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355. PubMedAbstract available
SHIYAM SUNDAR LK, Beyer T Is Automatic Tumor Segmentation on Whole-Body (18)F-FDG PET Images a Clinical
Reality?
J Nucl Med. 2024 Jun 6:jnumed.123.267183. doi: 10.2967/jnumed.123.267183. PubMedAbstract available
NADEL HR Innovation and Dedication Spur Excellence in Nuclear Medicine and Molecular
Imaging.
J Nucl Med. 2024;65:11A-12A. PubMed
BEEKMAN F, Czernin J, Mona C Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and
Christine Mona About Success in Academia and Industry.
J Nucl Med. 2024;65:826-828. PubMed
RICH AA, Taunk NK, Mankoff DA, Pantel AR, et al [(18)F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes.
J Nucl Med. 2024;65:990-991. PubMed
May 2024
LECY EE, Min HK, Apgar CJ, Maltais DD, et al Patterns of Early Neocortical Amyloid-beta Accumulation: A PET Population-Based
Study.
J Nucl Med. 2024 May 23:jnumed.123.267150. doi: 10.2967/jnumed.123.267150. PubMedAbstract available
IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107. PubMedAbstract available
SMEETS EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, et al Histology-Based Radiomics for [(18)F]FDG PET Identifies Tissue Heterogeneity in
Pancreatic Cancer.
J Nucl Med. 2024 May 23:jnumed.123.266262. doi: 10.2967/jnumed.123.266262. PubMedAbstract available
WATANABE M, Fendler WP, Grafe H, Hirmas N, et al Prognostic Implications of (68)Ga-FAPI-46 PET/CT-Derived Parameters on Overall
Survival in Various Types of Solid Tumors.
J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981. PubMedAbstract available
SADAGHIANI MS, Baskaran S, Gorin MA, Rowe SP, et al Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A
Systematic Review and Metaanalysis.
J Nucl Med. 2024 May 23:jnumed.124.267417. doi: 10.2967/jnumed.124.267417. PubMedAbstract available
FLEMING MT, Hermsen R, Purysko AS, Chau A, et al True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer
Recurrence with Baseline-Negative Conventional Imaging: Results from the
Prospective, Phase 3, Multicenter SPOTLIGHT Study.
J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271. PubMedAbstract available
HEIDARI P, Haj-Mirzaian A, Prabhu S, Ataeinia B, et al Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel
Disease.
J Nucl Med. 2024 May 16:jnumed.123.267344. doi: 10.2967/jnumed.123.267344. PubMedAbstract available
YADAV S, Jiang F, Kurkowska S, Saelee R, et al Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT
Imaging at 24 Hours After Injection.
J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208. PubMedAbstract available
CAOBELLI F, Gozlugol N, Bakula A, Rominger A, et al Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with
Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and
Preserved Left Ventricular Function.
J Nucl Med. 2024 May 9:jnumed.123.266926. doi: 10.2967/jnumed.123.266926. PubMedAbstract available
LANZAFAME H, Mavroeidi IA, Pabst KM, Desaulniers M, et al (68)Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of
Intermediate and Low-Grade Sarcomas and Identifies Candidates for
Radiopharmaceutical Therapy.
J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248. PubMedAbstract available
MILLER RJH, Shanbhag A, Michalowska AM, Kavanagh P, et al Deep Learning-Enabled Quantification of (99m)Tc-Pyrophosphate SPECT/CT for
Cardiac Amyloidosis.
J Nucl Med. 2024 May 9:jnumed.124.267542. doi: 10.2967/jnumed.124.267542. PubMedAbstract available
ZANG J, Yang Y, Chen S, Wang C, et al Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly
Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940. PubMedAbstract available
HOEK R, van Diemen PA, Raijmakers PG, Driessen RS, et al Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific
Cutoffs in Quantitative Myocardial Blood Flow Using [(15)O]H(2)O PET Imaging.
J Nucl Med. 2024 May 9:jnumed.123.267195. doi: 10.2967/jnumed.123.267195. PubMedAbstract available
DIETZ M, Kamani CH, Bousige C, Dunet V, et al Natural History of Myocardial alpha(v)beta(3) Integrin Expression After Acute Myocardial
Infarction: Correlation with Changes in Myocardial Blood Flow.
J Nucl Med. 2024 May 9:jnumed.124.267514. doi: 10.2967/jnumed.124.267514. PubMedAbstract available
WU Y, Sun T, Ng YL, Liu J, et al Clinical Implementation of Total-Body PET in China.
J Nucl Med. 2024;65. PubMedAbstract available
ZHANG J, Duan X, Chen X, Zhang Z, et al Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers
with (68)Ga-N188.
J Nucl Med. 2024;65. PubMedAbstract available
MENG X, Kong X, Xia L, Wu R, et al The Role of Total-Body PET in Drug Development and Evaluation: Status and
Outlook.
J Nucl Med. 2024;65. PubMedAbstract available
YANG W, Kang F, Chen Y, Zhu Z, et al Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
J Nucl Med. 2024;65. PubMedAbstract available
AN S, Wang L, Xie F, Jiang D, et al Pathway to Approval of Innovative Radiopharmaceuticals in China.
J Nucl Med. 2024;65. PubMedAbstract available
CHEN H, Shi K, Cai W, Li S, et al Advancing Global Nuclear Medicine: The Role and Future Contributions of China.
J Nucl Med. 2024;65. PubMed
ZHAO L, Kang F, Pang Y, Fang J, et al Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical,
Translational, and Clinical Status in China.
J Nucl Med. 2024;65. PubMedAbstract available
CHEN W, Li Y, Li Z, Jiang Y, et al Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center:
Insights from Sun Yat-sen University Cancer Center.
J Nucl Med. 2024;65. PubMedAbstract available
KLINE B, Yadav S, Seo Y, Ippisch RC, et al (68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison
with (18)F-FDG.
J Nucl Med. 2024 May 2:jnumed.123.267281. doi: 10.2967/jnumed.123.267281. PubMedAbstract available
MA Y, Zeng J, Ding F, Xu Y, et al Cerebral (18)F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous
System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
J Nucl Med. 2024 May 2:jnumed.123.267025. doi: 10.2967/jnumed.123.267025. PubMedAbstract available
FEHER A, Bednarski B, Miller RJ, Shanbhag A, et al Artificial Intelligence Predicts Hospitalization for Acute Heart Failure
Exacerbation in Patients Undergoing Myocardial Perfusion Imaging.
J Nucl Med. 2024;65:768-774. PubMedAbstract available
Gerald L. DeNardo, MD, 1932-2024.
J Nucl Med. 2024;65:823. PubMed
April 2024
ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain
Metastases: A Cost-Effectiveness Analysis.
J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687. PubMedAbstract available
NIKITAS J, Lam E, Booker KA, Fendler WP, et al Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive
Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer
(PSMA-dRT Trial).
J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. PubMedAbstract available
MINGELS C, Spencer BA, Nalbant H, Omidvari N, et al Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [(18)F]FDG
PET/CT.
J Nucl Med. 2024 Apr 25:jnumed.124.267521. doi: 10.2967/jnumed.124.267521. PubMedAbstract available
DUAN H, Song H, Davidzon GA, Moradi F, et al Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with
Biochemically Recurrent Prostate Cancer.
J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017. PubMedAbstract available
BURKETT BJ, Johnson DR, Lowe VJ Evaluation of Neurodegenerative Disorders with Amyloid-beta, Tau, and Dopaminergic
PET Imaging: Interpretation Pitfalls.
J Nucl Med. 2024 Apr 25:jnumed.123.266463. doi: 10.2967/jnumed.123.266463. PubMedAbstract available
GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA
Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant
Prostate Cancer.
J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234. PubMedAbstract available
LEUBE J, Gustafsson J, Lassmann M, Salas-Ramirez M, et al A Deep-Learning-Based Partial-Volume Correction Method for Quantitative (177)Lu
SPECT/CT Imaging.
J Nucl Med. 2024 Apr 18:jnumed.123.266889. doi: 10.2967/jnumed.123.266889. PubMedAbstract available
HAGENS MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, et al A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein
Inhibitor PET/CT in Genitourinary Cancers.
J Nucl Med. 2024 Apr 18:jnumed.123.267260. doi: 10.2967/jnumed.123.267260. PubMedAbstract available
MOSER R, Pfeiffer S, Cala L, Klein E, et al Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative
Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925. PubMedAbstract available
SWIHA M, Papa N, Sabahi Z, Ayati N, et al Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA
PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with
Quantitative SUV(mean) and Patient Outcomes.
J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014. PubMedAbstract available
QI C, Guo R, Chen Y, Li C, et al (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in
Gastrointestinal Cancer Patients.
J Nucl Med. 2024 Apr 11:jnumed.123.267110. doi: 10.2967/jnumed.123.267110. PubMedAbstract available
ROHRICH M, Daum J, Gutjahr E, Spektor AM, et al Diagnostic Potential of Supplemental Static and Dynamic (68)Ga-FAPI-46 PET for
Primary (18)F-FDG-Negative Pulmonary Lesions.
J Nucl Med. 2024 Apr 11:jnumed.123.267103. doi: 10.2967/jnumed.123.267103. PubMedAbstract available
O'DONNELL JL, Soda AK, Jiang H, Norris SA, et al PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest
Reproducibility and Age Dependence.
J Nucl Med. 2024 Apr 11:jnumed.123.266860. doi: 10.2967/jnumed.123.266860. PubMedAbstract available
VISCUSE P, Devitt M, Dreicer R Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical
Therapy Fit in the Treatment Algorithm?
J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006. PubMedAbstract available
WU Q, Gu F, O'Suilleabhain LD, Sari H, et al Mapping (18)F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of
Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial
Field of View.
J Nucl Med. 2024 Apr 11:jnumed.123.266686. doi: 10.2967/jnumed.123.266686. PubMedAbstract available
BARATTO L, Singh SB, Williams SE, Spunt SL, et al Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young
Adult Cancer Survivors Using [(18)F]FDG PET/MRI: A Pilot Study.
J Nucl Med. 2024 Apr 4:jnumed.123.266760. doi: 10.2967/jnumed.123.266760. PubMedAbstract available
GEBHART G, Keyaerts M, Guiot T, Flamen P, et al Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in
HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab
and Pertuzumab in the PHERGain Trial.
J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384. PubMedAbstract available
BISCHOF GN, Brendel M, Barthel H, Theis H, et al Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with
[(18)F]PI-2620.
J Nucl Med. 2024 Apr 4:jnumed.123.265930. doi: 10.2967/jnumed.123.265930. PubMedAbstract available
RUWANPATHIRANA GP, Williams RC, Masters CL, Rowe CC, et al Impact of PET Reconstruction on Amyloid-beta Quantitation in Cross-Sectional and
Longitudinal Analyses.
J Nucl Med. 2024 Apr 4:jnumed.123.266188. doi: 10.2967/jnumed.123.266188. PubMedAbstract available
SCHULER M, Hense J, Darwiche K, Michels S, et al Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted
Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired
Resistance.
J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979. PubMedAbstract available
LI Z, Benabdallah N, Luo J, Wahl RL, et al ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT
Method Across Multiple Scanner-Collimator Configurations for (223)Ra-Based
Radiopharmaceutical Therapies.
J Nucl Med. 2024 Apr 4:jnumed.123.266719. doi: 10.2967/jnumed.123.266719. PubMedAbstract available
March 2024
ALTENA R, Buren SA, Blomgren A, Karlsson E, et al Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast
Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847. PubMedAbstract available
COLLARINO A, Feudo V, Pasciuto T, Florit A, et al Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in
Locally Advanced Cervical Cancer?
J Nucl Med. 2024 Mar 28:jnumed.123.267044. doi: 10.2967/jnumed.123.267044. PubMedAbstract available
BLAKKISRUD J, Peterson AB, Wildermann SJ, Kingkiner G, et al SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic
Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
J Nucl Med. 2024 Mar 28:jnumed.123.266843. doi: 10.2967/jnumed.123.266843. PubMedAbstract available
ZHANG X, Heo GS, Li A, Lahad D, et al Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages
in Atherosclerosis.
J Nucl Med. 2024 Mar 28:jnumed.123.266910. doi: 10.2967/jnumed.123.266910. PubMedAbstract available
WANG Y, Abdelhafez YG, Spencer BA, Verma R, et al High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input
Function Using Total-Body Dynamic PET.
J Nucl Med. 2024 Mar 28:jnumed.123.267036. doi: 10.2967/jnumed.123.267036. PubMedAbstract available
HAIDER SP, Zeevi T, Sharaf K, Gross M, et al Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of
Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637. PubMedAbstract available
PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional
Pituitary Tumors.
J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853. PubMedAbstract available
LIU N, Yang X, Gao C, Wang J, et al Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using
Galectin-1 PET to Inform Immunotherapy Responses.
J Nucl Med. 2024 Mar 21:jnumed.123.266888. doi: 10.2967/jnumed.123.266888. PubMedAbstract available
JAGUST WJ, Mattay VS, Krainak DM, Wang SJ, et al Quantitative Brain Amyloid PET.
J Nucl Med. 2024 Mar 21:jnumed.123.265766. doi: 10.2967/jnumed.123.265766. PubMedAbstract available
CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in
Gastroesophageal Cancer.
J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186. PubMedAbstract available
SHI J, Li D, Chen M, Fu Y, et al The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions
on Multiparametric MRI: A Prospective Single-Center Study.
J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742. PubMedAbstract available
BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe
Signal for Intraoperative Identification of Prostate Cancer Lesions.
J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075. PubMedAbstract available
SAHIN E, Kus T, Aytekin A, Uzun E, et al (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of
Invasive Lobular Breast Carcinoma.
J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798. PubMedAbstract available
PORTER JC, Ganeshan B, Win T, Fraioli F, et al [(18)F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with
Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the
Use of PET/CT in Diffuse Lung Diseases.
J Nucl Med. 2024 Mar 14:jnumed.123.266445. doi: 10.2967/jnumed.123.266445. PubMedAbstract available
PROVIDENCIA L, van der Weijden CWJ, Mohr P, van Sluis J, et al Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET
Studies?
J Nucl Med. 2024 Mar 14:jnumed.123.266675. doi: 10.2967/jnumed.123.266675. PubMedAbstract available
THOR M, Lee C, Sun L, Patel P, et al An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation
Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with
Chemoradiation and Immunotherapy.
J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965. PubMedAbstract available
DRESCHER R, Greiser J, Grober S, Weisheit T, et al (64)Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal
Fluid Space.
J Nucl Med. 2024 Mar 14:jnumed.123.267329. doi: 10.2967/jnumed.123.267329. PubMed
HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate
Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702. PubMedAbstract available
LI C, Chen Q, Tian Y, Chen J, et al (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph
Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806. PubMedAbstract available
HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in
Independent Cohorts of Non-Small Cell Lung Cancer Patients.
J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331. PubMedAbstract available
CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on
[(68)Ga]Ga-FAPI PET/CT.
J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155. PubMed
FAROLFI A, Armstrong WR, Djaileb L, Gafita A, et al Differences and Common Ground in (177)Lu-PSMA Radioligand Therapy Practice
Patterns: International Survey of 95 Theranostic Centers.
J Nucl Med. 2024;65:438-445. PubMedAbstract available
February 2024
LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor
Quantification and Prognosis of Cancer on PET/CT.
J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048. PubMedAbstract available
JIANG M, Tang S, Jenkins MD, Lee AC, et al Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and
(11)C-Labeled Radioligands That Avoid Radiometabolite Contamination.
J Nucl Med. 2024 Feb 29:jnumed.123.266750. doi: 10.2967/jnumed.123.266750. PubMedAbstract available
GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with
Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189. PubMed
BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in
Metastatic Castration-Resistant Prostate Cancer Patients.
J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654. PubMedAbstract available
EL FAKIRI M, Ayada N, Muller M, Hvass L, et al Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for
Targeted alpha-Therapy of Prostate Cancer.
J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043. PubMedAbstract available
KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of
Head and Neck Cancer.
J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574. PubMedAbstract available
LI G, Ma W, Li X, Yang W, et al Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the
National Electrical Manufacturers Association NU 2-2018 Standard.
J Nucl Med. 2024 Feb 22:jnumed.123.265929. doi: 10.2967/jnumed.123.265929. PubMedAbstract available
SLART RHJA, Bengel FM, Akincioglu C, Bourque JM, et al Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document
of the SNMMI Cardiovascular Council.
J Nucl Med. 2024 Feb 22:jnumed.123.266858. doi: 10.2967/jnumed.123.266858. PubMedAbstract available
BOURBONNE V, Morjani M, Pradier O, Hatt M, et al PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small
Cell Lung Cancer Treated with Curative Radiotherapy.
J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749. PubMedAbstract available
LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al Example of Artificial Intelligence-Based Decision Support for Amino Acid PET:
Early Prediction of Suspected Brain Tumor Foci for Patient Management.
J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112. PubMed
DRAKE LR, Wu Y, Naganawa M, Asch R, et al First-in-Human Study of (18)F-SynVesT-2: An SV2A PET Imaging Probe with Fast
Brain Kinetics and High Specific Binding.
J Nucl Med. 2024 Feb 15:jnumed.123.266470. doi: 10.2967/jnumed.123.266470. PubMedAbstract available
LIU Z, Mhlanga JC, Xia H, Siegel BA, et al Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for
Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial
Data.
J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018. PubMedAbstract available
KISHAN AU, Siva S, Hofman MS, Nagarajah J, et al The Potential Contribution of Radiopharmaceutical Therapies in Managing
Oligometastatic Disease.
J Nucl Med. 2024 Feb 15:jnumed.123.266772. doi: 10.2967/jnumed.123.266772. PubMedAbstract available
DUBASH S, Barwick TD, Kozlowski K, Rockall AG, et al Somatostatin Receptor Imaging with [(18)F]FET-betaAG-TOCA PET/CT and
[(68)Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A
Prospective, Phase 2 Comparative Study.
J Nucl Med. 2024 Feb 8:jnumed.123.266601. doi: 10.2967/jnumed.123.266601. PubMedAbstract available
HIRMAS N, Hamacher R, Sraieb M, Kessler L, et al Diagnostic Accuracy of (68)Ga-FAPI Versus (18)F-FDG PET in Patients with Various
Malignancies.
J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652. PubMedAbstract available
GONDRY O, Caveliers V, Xavier C, Raes L, et al Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2
Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
J Nucl Med. 2024;65:178-184. PubMedAbstract available
OH M, Oh SJ, Lee SJ, Oh JS, et al One-Year Longitudinal Changes in Tau Accumulation on [(18)F]PI-2620 PET in the
Alzheimer Spectrum.
J Nucl Med. 2024 Feb 1:jnumed.123.265893. doi: 10.2967/jnumed.123.265893. PubMedAbstract available
SOULEN MC, Rilling WS Clinical Outcomes After Personalized Dosimetry for (90)Y Radioembolization of
Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a
Pharma-Centric Landscape.
J Nucl Med. 2024;65:270-271. PubMed
AL MANSOUR L, De Mestier L, Haissaguerre M, Afchain P, et al Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors
Treated by (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth
Study, a National Study from the French Group of Endocrine Tumors and
Endocan-RENATEN Networ
J Nucl Med. 2024;65:258-263. PubMedAbstract available
HAMACHER R, Pabst KM, Cheung PF, Heilig CE, et al Fibroblast Activation Protein alpha-Directed Imaging and Therapy of Solitary Fibrous
Tumor.
J Nucl Med. 2024;65:252-257. PubMedAbstract available
WAGEMANS MEHM, Kunnen B, Stella M, van Rooij R, et al Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally
Advanced Intrahepatic Cholangiocarcinoma.
J Nucl Med. 2024;65:272-278. PubMedAbstract available
HE Y, Kramer SD, Grether U, Wittwer MB, et al Identification of (R)-[(18)F]YH134 for Monoacylglycerol Lipase Neuroimaging and
Exploration of Its Use for Central Nervous System and Peripheral Drug
Development.
J Nucl Med. 2024;65:300-305. PubMedAbstract available
MILEVA M, Marin G, Levillain H, Artigas C, et al Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in
Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a
Prospective Phase II LUMEN Study.
J Nucl Med. 2024;65:236-244. PubMedAbstract available
GIRUM KB, Cottereau AS, Vercellino L, Rebaud L, et al Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma
Patients: A Demonstration from the REMARC Trial.
J Nucl Med. 2024;65:313-319. PubMedAbstract available
CHIESA C, Bagnalasta M, Maccauro M Good Voxel Dosimetry with a Simplified Study Design Resulted in Improvable Safety
Limits.
J Nucl Med. 2024;65:331-332. PubMed
January 2024
GU B, Yang Z, Du X, Xu X, et al Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy
of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative
Imaging Trial.
J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556. PubMedAbstract available
KIRBY A, Graf D, Suchy M, Calvert ND, et al It's a Trap! Aldolase-Prescribed C(4) Deoxyradiofluorination Affords
Intracellular Trapping and the Tracing of Fructose Metabolism by PET.
J Nucl Med. 2024 Jan 25:jnumed.123.266905. doi: 10.2967/jnumed.123.266905. PubMedAbstract available
YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in
Patients with HER2-Positive Breast Cancer.
J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392. PubMedAbstract available
BUCHERT R, Szabo B, Kovacs A, Buddenkotte T, et al Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole
Collimators.
J Nucl Med. 2024 Jan 18:jnumed.123.266276. doi: 10.2967/jnumed.123.266276. PubMedAbstract available
LIGHT A, Lazic S, Houghton K, Bayne M, et al Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for
Detection of Intraprostatic Radiorecurrent Prostate Cancer.
J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527. PubMedAbstract available
BARLATEY SL, Mignardot CG, Friedrichs-Maeder C, Schindler K, et al Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study.
J Nucl Med. 2024 Jan 11:jnumed.123.266515. doi: 10.2967/jnumed.123.266515. PubMedAbstract available
KOSHKIN VS, Kumar V, Kline B, Escobar D, et al Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial
Cancer.
J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390. PubMedAbstract available
UNTERRAINER LM, Memarzadeh S, Moatamed NA, Benz MR, et al [(68)Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732. PubMed
HOPE TA, Jadvar H PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
J Nucl Med. 2024 Jan 4:jnumed.123.267042. doi: 10.2967/jnumed.123.267042. PubMed
UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722. PubMed
DE WINTER RW, van Diemen PA, Schumacher SP, Jukema RA, et al Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous
Wave-Free Ratio Assessment Through Quantitative [(15)O]H(2)O PET Myocardial
Perfusion Imaging.
J Nucl Med. 2024 Jan 4:jnumed.123.265973. doi: 10.2967/jnumed.123.265973. PubMedAbstract available
RAHBAR K, Boegemann M The Imperative for Comparative Studies in Nuclear Medicine: Elevating
(177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952. PubMed
LI X, Lu N, Lin L, Chen Y, et al (18)F-FAPI-04 Outperforms (18)F-FDG PET/CT in Clinical Assessments of Patients
with Pancreatic Adenocarcinoma.
J Nucl Med. 2024 Jan 4:jnumed.123.266283. doi: 10.2967/jnumed.123.266283. PubMedAbstract available
ZHAO L, Pang Y, Fang J, Chen J, et al Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a
Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183. PubMedAbstract available
STRUNK M, Heo GS, Hess A, Luehmann H, et al Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial
Infarction: Evaluation of the Immune-Fibrosis Axis.
J Nucl Med. 2024 Jan 4:jnumed.123.266526. doi: 10.2967/jnumed.123.266526. PubMedAbstract available
SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node
Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of
Locoregional Lymph Node Metastases: The DETECT Trial.
J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495. PubMedAbstract available
SPEKTOR AM, Gutjahr E, Lang M, Glatting FM, et al Immunohistochemical FAP Expression Reflects (68)Ga-FAPI PET Imaging Properties of
Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic
Ductal Adenocarcinoma.
J Nucl Med. 2024;65:52-58. PubMedAbstract available
PAPPAS V, Czernin J Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes
Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
J Nucl Med. 2024;65:1-3. PubMed
POPLAWSKI SE, Hallett RM, Dornan MH, Novakowski KE, et al Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation
Protein-alpha (FAP)-Targeted Radiotheranostic for Imaging and Treatment of
FAP-Positive Tumors.
J Nucl Med. 2024;65:100-108. PubMedAbstract available
MALIHA PG, Hotta M, Czernin J, Calais J, et al Characterizing Normal Variant [(68)Ga]Ga-FAPI-46 Uptake in the Epididymis.
J Nucl Med. 2024;65:59-62. PubMedAbstract available
LUTHRIA G, Baratto L, Adams L, Morakote W, et al Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology
Patients After Coronavirus Disease 2019 Vaccination.
J Nucl Med. 2024;65:22-24. PubMedAbstract available
ENKE JS, Reitsam NG, Grosser B, Kircher M, et al C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using
[(99m)Tc]Tc-PentixaTec.
J Nucl Med. 2024;65:163-164. PubMed
December 2023
CHAN DL, Hayes AR, Karfis I, Conner A, et al [(18)F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with
Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
J Nucl Med. 2023 Dec 21:jnumed.123.266346. doi: 10.2967/jnumed.123.266346. PubMedAbstract available
MIAO Y, Feng R, Yu T, Guo R, et al Value of (68)Ga-FAPI-04 and (18)F-FDG PET/CT in Early Prediction of Pathologic
Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
J Nucl Med. 2023 Dec 21:jnumed.123.266403. doi: 10.2967/jnumed.123.266403. PubMedAbstract available
VENTURA D, Dittmann M, Buther F, Schafers M, et al Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity
[(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid
Carcinoma.
J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513. PubMedAbstract available
DIERKS A, Gable A, Rinscheid A, Wienand G, et al First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the
Treatment of Metastatic Prostate Cancer.
J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741. PubMedAbstract available
BARTLETT EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, et al Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard
Scanner.
J Nucl Med. 2023 Dec 14:jnumed.122.265309. doi: 10.2967/jnumed.122.265309. PubMedAbstract available
FETTAHOGLU A, Zhao M, Khalighi M, Vossler H, et al Early-Frame [(18)F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in
Patients with Cognitive Impairment: Comparison to an [(15)O]Water Gold Standard.
J Nucl Med. 2023 Dec 7:jnumed.123.266273. doi: 10.2967/jnumed.123.266273. PubMedAbstract available
MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor
Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938. PubMedAbstract available
NADEL HR A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.
J Nucl Med. 2023;64:1843-1844. PubMed
BLAZHENETS G, Soleimani-Meigooni DN, Thomas W, Mundada N, et al [(18)F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and
Frontotemporal Lobar Degeneration.
J Nucl Med. 2023;64:1980-1989. PubMedAbstract available
FANI M, Nicolas GP (61)Cu-Labeled Radiotracers: Alternative or Choice?
J Nucl Med. 2023;64:1855-1857. PubMed
November 2023
EMMETT L, Papa N, Counter W, Calais J, et al Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on
Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164. PubMedAbstract available
WANG F, Liu C, Vidal I, Mana-Ay M, et al Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary
Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL
PET/CT.
J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005. PubMedAbstract available
DING J, Li X, Liu S, Gao Y, et al Clinical Value of (68)Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary
Aldosteronism Patients with Adrenal Micronodules.
J Nucl Med. 2023 Nov 30:jnumed.123.266061. doi: 10.2967/jnumed.123.266061. PubMedAbstract available
KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels
and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A
Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158. PubMedAbstract available
PUUVUORI E, Shen Y, Hulsart-Billstrom G, Mitran B, et al Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical
Disease in Inflammatory Arthritis.
J Nucl Med. 2023 Nov 30:jnumed.123.266336. doi: 10.2967/jnumed.123.266336. PubMedAbstract available
NDLOVU H, Lawal I, Mokoala K, Disenyane D, et al Imaging PARP Upregulation with [(123)I]I-PARPi SPECT/CT in Small Cell
Neuroendocrine Carcinoma.
J Nucl Med. 2023 Nov 30:jnumed.123.266348. doi: 10.2967/jnumed.123.266348. PubMed
DOERING E, Antonopoulos G, Hoenig M, van Eimeren T, et al MRI or (18)F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology,
and Alzheimer Disease Progression.
J Nucl Med. 2023 Nov 30:jnumed.123.265931. doi: 10.2967/jnumed.123.265931. PubMedAbstract available
KURONUMA K, Wei CC, Singh A, Lemley M, et al Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic
Performance of (82)Rb PET Myocardial Perfusion Imaging.
J Nucl Med. 2023 Nov 30:jnumed.123.266208. doi: 10.2967/jnumed.123.266208. PubMedAbstract available
QUAN Z, Han Z, Yang Y, Wang J, et al Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation
Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002. PubMedAbstract available
KESSLER L, Hirmas N, Pabst KM, Hamacher R, et al (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for
Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial.
J Nucl Med. 2023 Nov 16:jnumed.122.264827. doi: 10.2967/jnumed.122.264827. PubMedAbstract available
NAMMAS W, Paunonen C, Teuho J, Siekkinen R, et al Imaging of Myocardial alpha(v)beta(3) Integrin Expression for Evaluation of Myocardial
Injury After Acute Myocardial Infarction.
J Nucl Med. 2023 Nov 16:jnumed.123.266148. doi: 10.2967/jnumed.123.266148. PubMedAbstract available
BALAJI V, Song TA, Malekzadeh M, Heidari P, et al Artificial Intelligence for PET and SPECT Image Enhancement.
J Nucl Med. 2023 Nov 9:jnumed.122.265000. doi: 10.2967/jnumed.122.265000. PubMedAbstract available
GUNTHER T, Holzleitner N, Viering O, Beck R, et al Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept
[(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537. PubMedAbstract available
CARLIER T, Frecon G, Mateus D, Rizkallah M, et al Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided
Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning
Analysis from the GAINED Study.
J Nucl Med. 2023 Nov 9:jnumed.123.265872. doi: 10.2967/jnumed.123.265872. PubMedAbstract available
CHEN L, Zheng S, Chen L, Xu S, et al (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and
Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast
Cancer Patients: A Prospective Study.
J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079. PubMedAbstract available
REZAZADEH F, Kilcline AP, Viola NT Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
J Nucl Med. 2023 Nov 2:jnumed.123.265935. doi: 10.2967/jnumed.123.265935. PubMedAbstract available
VIERING O, Gunther T, Holzleitner N, Dierks A, et al CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using
[(68)Ga]Ga-DOTA-CCK-66.
J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380. PubMed
GEBHART G (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast
Cancer: Quo Vadis?
J Nucl Med. 2023;64:1697-1698. PubMed
KNUUTI J, Tuisku J, Karpijoki H, Iida H, et al Quantitative Perfusion Imaging with Total-Body PET.
J Nucl Med. 2023;64. PubMedAbstract available
DI CARLI MF Future of Radionuclide Myocardial Perfusion Imaging: Transitioning from SPECT to
PET.
J Nucl Med. 2023;64. PubMed
BENGEL FM, Di Carli MF The Evolution of Cardiac Nuclear Imaging.
J Nucl Med. 2023;64. PubMed
ROLL W, Faust A, Hermann S, Schafers M, et al Infection Imaging: Focus on New Tracers?
J Nucl Med. 2023;64. PubMedAbstract available
LI EJ, Lopez JE, Spencer BA, Abdelhafez Y, et al Total-Body Perfusion Imaging with [(11)C]-Butanol.
J Nucl Med. 2023;64:1831-1838. PubMedAbstract available
October 2023
KAYAL G, Barbosa N, Calderon Marin C, Ferrer L, et al Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using
PLANETDose: An International Atomic Energy Agency Study.
J Nucl Med. 2023 Oct 26:jnumed.122.265340. doi: 10.2967/jnumed.122.265340. PubMedAbstract available
MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying
Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868. PubMedAbstract available
XU W, Cai J, Peng T, Meng T, et al Fibroblast Activation Protein-Targeted PET/CT with (18)F-Fibroblast Activation
Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with
(18)F-FDG PET/CT.
J Nucl Med. 2023 Oct 26:jnumed.123.266329. doi: 10.2967/jnumed.123.266329. PubMedAbstract available
LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in
Patients with Papillary Thyroid Carcinoma.
J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044. PubMedAbstract available
KAIREMO K, Czernin J Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin
Discusses Innovation and Translation with Kalevi Kairemo.
J Nucl Med. 2023 Oct 19:jnumed.123.266793. doi: 10.2967/jnumed.123.266793. PubMed
YAMAGISHI S, Miwa K, Kamitaki S, Anraku K, et al Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide
PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.
J Nucl Med. 2023 Oct 19:jnumed.123.266140. doi: 10.2967/jnumed.123.266140. PubMedAbstract available
LI X, Ye J, Wang J, Quan Z, et al First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung
and Colorectal Cancer Patients Using [(18)F]PFPMD.
J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715. PubMedAbstract available
WATABE T, Kabayama K, Naka S, Yamamoto R, et al Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with
(89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
J Nucl Med. 2023 Oct 12:jnumed.123.266313. doi: 10.2967/jnumed.123.266313. PubMedAbstract available
AL-TOUBAH T, Montilla-Soler J, El-Haddad G, Haider M, et al Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of
DOTATATE PET Scans.
J Nucl Med. 2023 Oct 5:jnumed.123.266185. doi: 10.2967/jnumed.123.266185. PubMedAbstract available
DUELL J, Buck AK, Hartrampf PE, Schlotelburg W, et al Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in
Marginal Zone Lymphoma.
J Nucl Med. 2023 Oct 5:jnumed.123.266074. doi: 10.2967/jnumed.123.266074. PubMedAbstract available
SCHEUERMANN JS, Pryma DA Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy
Dosimetry Methodologies.
J Nucl Med. 2023;64:1617-1618. PubMed
CHICHEPORTICHE A, Sason M, Zidan M, Godefroy J, et al Impact of Single-Time-Point Estimates of (177)Lu-PRRT Absorbed Doses on Patient
Management: Validation of a Trained Multiple-Linear-Regression Model in 159
Patients and 477 Therapy Cycles.
J Nucl Med. 2023;64:1610-1616. PubMedAbstract available
GANZ PA, Czernin J Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin
Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
J Nucl Med. 2023;64:1506-1508. PubMed
MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of
Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
J Nucl Med. 2023;64:1632-1637. PubMedAbstract available
KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds
RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
J Nucl Med. 2023;64:1654-1659. PubMedAbstract available
COOK BE, Nag S, Arakawa R, Lin EY, et al Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
J Nucl Med. 2023;64:1588-1593. PubMedAbstract available
HERINGTON J, McCradden MD, Creel K, Boellaard R, et al Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment
and Governance.
J Nucl Med. 2023;64:1509-1515. PubMedAbstract available
September 2023
SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients
with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen
Receptor Pathway Inhibitors.
J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874. PubMedAbstract available
HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission
and Detecting Recurrence.
J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446. PubMed
CONSTANTINESCU CC, Brown T, Wang S, Yin W, et al Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET
Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.
J Nucl Med. 2023 Sep 28:jnumed.123.265912. doi: 10.2967/jnumed.123.265912. PubMedAbstract available
ALBERTO S, Ordonez AA, Arjun C, Aulakh GK, et al The Development and Validation of Radiopharmaceuticals Targeting Bacterial
Infection.
J Nucl Med. 2023 Sep 28:jnumed.123.265906. doi: 10.2967/jnumed.123.265906. PubMedAbstract available
CHAN CY, Chen Z, Guibbal F, Dias G, et al [(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for
Radionuclide Therapy of Cancer.
J Nucl Med. 2023 Sep 28:jnumed.123.265429. doi: 10.2967/jnumed.123.265429. PubMedAbstract available
SCHMIDKONZ C, Atzinger A, Ramming A, Kuwert T, et al FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic
Disorders.
J Nucl Med. 2023 Sep 21:jnumed.123.266182. doi: 10.2967/jnumed.123.266182. PubMed
KLUGE K, Haberl D, Einspieler H, Rasul S, et al Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in
Patients with Prostate Cancer.
J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980. PubMedAbstract available
ITTI E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, et al Validation of the DeltaSUV(max) for Interim PET Interpretation in Diffuse Large
B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
J Nucl Med. 2023 Sep 21:jnumed.123.265871. doi: 10.2967/jnumed.123.265871. PubMedAbstract available
DEMMERT TT, Pomykala KL, Lanzafame H, Pabst KM, et al Oncologic Staging with (68)Ga-FAPI PET/CT Demonstrates a Lower Rate of
Nonspecific Lymph Node Findings Than (18)F-FDG PET/CT.
J Nucl Med. 2023 Sep 21:jnumed.123.265751. doi: 10.2967/jnumed.123.265751. PubMedAbstract available
ROGASCH JMM, Metzger G, Preisler M, Galler M, et al ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My
Reports?
J Nucl Med. 2023 Sep 14:jnumed.123.266114. doi: 10.2967/jnumed.123.266114. PubMedAbstract available
ALTENA R, Af Buren S, Tran T, Axelsson R, et al HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101. PubMed
SEBAN RD Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490. PubMed
GEORGOULIAS P, Angelidis G, Koukouraki S, Koutsikos J, et al Debating the Future of Nuclear Medicine: The Greek Experience.
J Nucl Med. 2023 Sep 14:jnumed.123.266646. doi: 10.2967/jnumed.123.266646. PubMed
GOGOLA A, Lopresti BJ, Tudorascu D, Snitz B, et al Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human
Tau PET Imaging Studies.
J Nucl Med. 2023 Sep 14:jnumed.123.265941. doi: 10.2967/jnumed.123.265941. PubMed
KOERBER SA, Rohrich M, Walkenbach L, Liermann J, et al Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of
226 Patients with Various Cancers.
J Nucl Med. 2023 Sep 7:jnumed.123.266046. doi: 10.2967/jnumed.123.266046. PubMedAbstract available
MURTHY V, Gafita A, Thin P, Nguyen K, et al Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
(177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155. PubMedAbstract available
SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and
Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of
Skin-Absorbed Dose'".
J Nucl Med. 2023 Sep 7:jnumed.123.266596. doi: 10.2967/jnumed.123.266596. PubMed
KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer
Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878. PubMedAbstract available
MANKOFF D The Future of Nuclear Medicine.
J Nucl Med. 2023;64:1329-1330. PubMed
KRAEBER-BODERE F, Jamet B, Bezzi D, Zamagni E, et al New Developments in Myeloma Treatment and Response Assessment.
J Nucl Med. 2023;64:1331-1343. PubMedAbstract available
WANG C, Peterson AB, Wong KK, Roseland ME, et al Single-Time-Point Imaging for Dosimetry After [(177)Lu]Lu-DOTATATE: Accuracy of
Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to
Time-Point Selection.
J Nucl Med. 2023;64:1463-1470. PubMedAbstract available
HARTLAPP I, Hartrampf PE, Serfling SE, Wild V, et al CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell
Tumors.
J Nucl Med. 2023;64:1424-1430. PubMedAbstract available
PANG Y, Zhao L, Fang J, Chen J, et al Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI
Radioligand Therapy.
J Nucl Med. 2023;64:1449-1455. PubMedAbstract available
AHMAD AA, Ghim M, Toczek J, Neishabouri A, et al Multimodality Imaging of Aortic Valve Calcification and Function in a Murine
Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve.
J Nucl Med. 2023;64:1487-1494. PubMedAbstract available
August 2023
ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with
[(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546. PubMedAbstract available
EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial
Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025. PubMed